Sandbox UC 10
From Proteopedia
(Difference between revisions)
Line 7: | Line 7: | ||
- | [[Image:1dxx.png | + | [[Image:1dxx.png|200px|thumb|Crystal Structure of Human dystrophin, [[1dxx]]]] |
- | [[Image:imag1gonzalo.jpg | + | [[Image:imag1gonzalo.jpg|200px|thumb|Comparacion de la degeneracion muscular, [[1dxx]]]] |
- | [[Image:MW_Folding_Simulations.gif | + | [[Image:MW_Folding_Simulations.gif|200px|thumb|[[1dxx]]]] |
---- | ---- | ||
Line 22: | Line 22: | ||
---- | ---- | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
<quiz display=simple> | <quiz display=simple> | ||
{la pregunta va aquí | Type = "[]"} | {la pregunta va aquí | Type = "[]"} |
Revision as of 19:40, 19 December 2012
N-TERMINAL ACTIN-BINDING DOMAIN OF HUMAN DYSTROPHIN
Dystrophin is an essential component of skeletal muscle cells. Its N-terminal domain binds to F-actin and its C terminus binds to the dystrophin-associated glycoprotein (DAG) complex in the membrane.

Crystal Structure of Human dystrophin, 1dxx

Comparacion de la degeneracion muscular, 1dxx
Amino Terminus | Carboxy Terminus |
- ↑ Nadeau D, Marchand C. Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76. PMID:1234
- ↑ Rubinstein MH. A new granulation method for compressed tablets [proceedings]. J Pharm Pharmacol. 1976 Dec;28 Suppl:67P. PMID:12345